The Biorepositories and Biospecimen Research Branch (BBRB) at the National Cancer Institute (NCI) has sponsored various initiatives for conducting biospecimen research. Through these initiatives, NCI seeks to advance biospecimen science and improve research reproducibility by investigating how different biospecimen collection, handling and processing procedures affect biospecimen molecular profiles. BBRB is seeking collaborators to extend these studies.
Engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions. NCI seeks partners to license and/or co-develop this technology toward commercialization.
The National Cancer Institute seeks parties interested in collaborative research to co-develop or license methods of treating disorders related to polyomavirus, as well as vaccines for patients undergoing immunosuppressive treatment such as multiple sclerosis, rheumatoid arthritis, B cell cancers, and Crohn’s disease.